T1	Participants 101 157	women with ErbB2 overexpressing metastatic breast cancer
T2	Participants 607 927	open-label, multicenter, phase II study, eligible patients (N = 112) were randomized 2:1 to lapatinib plus vinorelbine [(N = 75) 1,250 mg orally once daily (QD) continuously plus 20 mg/m(2)/day intravenously] or lapatinib plus capecitabine [(N = 37) 1,250 mg orally QD continuously plus 2,000 mg/m(2)/day orally, 2 doses
T3	Participants 1047 1203	Patients progressing within the study were given the option of crossover to the other treatment arm; time to second progression was an exploratory endpoint.
T4	Participants 1204 1302	Patient demographics, stratification, and prognostic factors were well balanced between treatments
